WPD Pharmaceuticals Inc. announced that in respect to its sublicense agreement with CNS Pharmaceuticals Inc. on December 23, 2021, CNS confirmed that the company has used “commercially reasonable development efforts” towards the development of Berubicin, defined as expenditures of at least USD 2,000,000 on the development, testing, regulatory approval or commercialization of the licensed product during the applicable development period, and as such, the Company, through WPD Poland, is entitled to maintain its sublicense of Berubicin subject to the ongoing obligations under the CNS Agreement. The Company's sub-license of Berubicin allows it geographic exclusivity for development and marketing in a region consisting of select countries in Eastern Europe and Central Asia.